With a one year PEG ratio of 4,997.78, Syros Pharmaceuticals Inc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 99.18% of US stocks.
SYRS's price/sales ratio is 52.41; that's higher than the P/S ratio of 94.41% of US stocks.
As for revenue growth, note that SYRS's revenue has grown 318.38% over the past 12 months; that beats the revenue growth of 97.81% of US companies in our set.
Stocks with similar financial metrics, market capitalization, and price volatility to Syros Pharmaceuticals Inc are CNCE, AGIO, CMRX, DRNA, and ALPN.
Syros Pharmaceuticals, Inc. - common stock (SYRS) Company Bio
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing medicines that control genes to transform the lives of patients with cancer, immune-mediated diseases, and other diseases. The company was founded in 2011 and is based in Cambridge, Massachusetts.
Syros Pharmaceuticals (SYRS) has priced its public offering of 5.4M common shares at $14.00/share, which would result in gross proceeds of ~$75.6M.Underwriters' over-allotment is an additional 810K shares.The proceeds are expected to be used for the development of ongoing clinical and preclinical programs, for working capital and other general corporate...
Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, announced today that it has priced an underwritten public offering of 5,400,000 shares of common stock at a public offering price of $14.00 per share, which would result in gross proceeds of approximately $75.6 million, before underwriting discounts and commissions. The proceeds of the offering are expected to be used to fund the development of Syros’ ongoing clinical and preclinical programs, and for working capital and other general corporate purposes. All shares are being offered by Syros. Closing of the offering is expected to occur on or about January 22, 2021, subject to customary closing conditions. Syros has also granted the underwriters a 30-day option to purchas...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will present a corporate overview at the virtual 39th Annual J.P. Morgan Healthcare Conference. Details are as follows: 39th Annual J.P. Morgan Healthcare Conference: Date: Thursday, January 7 Time: 2:50 p.m. ET A live webcast of the presentation will be available on the Inve